Medical and Clinical Laboratory Technologists
29-2011.00Rank #459 of 923 scored · top 50% by substitution
Perform complex medical laboratory tests for diagnosis, treatment, and prevention of disease. May train or supervise staff.
Sub-scores
0–100 · band = confidence interval from rater disagreement
Substitution28
Exposure28
Augmentation55
Substitution — the headline: capability discounted by cost, barriers and adoption.
Exposure — technical capability alone, regardless of whether anyone deploys it.
Augmentation — how much AI assists without replacing. High here + moderate substitution = a changing job, not a disappearing one.
Tasks on the substitution scale
15 rated tasks, binned by substitution score.
Position among all scored occupations
Distribution of 923 occupation scores; the marker is this occupation.
Tasks with substitution ≥ 70
7%
Run 1.0.0-draft.1 · computed 2026-08-05 · rater panel: claude-sonnet-5, claude-haiku-4-5-20251001 · intervals span rater disagreement.
Why this score
The five weighted dimensions of the composite, averaged across this occupation's tasks (importance-weighted, panel mean). Exact weights and formulas: /api/v1/methodology.
Task automatabilityw 35%29
panel mean rating 2.1/5 → substitution pressure 29/100
Technical feasibility todayw 20%26
panel mean rating 2.0/5 → substitution pressure 26/100
Cost vs. human wagew 15%24
panel mean rating 2.0/5 → substitution pressure 24/100
Adoption barriersw 20%inverted — strong barriers lower the score31
panel mean rating 3.8/5 (barrier strength) → substitution pressure 31/100
Sector adoption velocityw 10%30
panel mean rating 2.2/5 → substitution pressure 30/100
Task breakdown (15 tasks)
Substitution pressure per task, weighted by O*NET importance in the composite. Expand a task for the full rater audit trail — every rating, every model, every rationale.
Enter data from analysis of medical tests or clinical results into computer for storage.
81CI 75–87 · exposure 83 · augmentation 63 · importance 4.8/5 · click for rater detail
Enter data from analysis of medical tests or clinical results into computer for storage.
81| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 4/5 | Healthcare IT adoption of automated lab data capture has accelerated substantially; major EHR vendors (Epic, Cerner) now include ML-driven ingestion as standard, and hospitals actively deploy these to reduce tech time. Adoption is deep in well-digitized hospital systems. |
| Sector adoption velocity | claude-sonnet-5 | 4/5 | Clinical laboratories have adopted LIS and instrument interfacing broadly over the past two decades, representing mature, widespread automation in this specific sub-task. |
| Augmentation potential | claude-haiku-4-5-20251001 | 4/5 | AI assists technologists by pre-populating or auto-validating data entry, reducing manual keystroke burden while allowing technicians to review and confirm results. This raises throughput and accuracy without removing human oversight of critical values. |
| Augmentation potential | claude-sonnet-5 | 3/5 | Where full interfacing isn't in place, AI-assisted transcription, OCR, and validation flags can speed up manual entry and reduce errors, though the task is largely already automated rather than augmented. |
| Task automatability | claude-haiku-4-5-20251001 | 5/5 | Data entry from structured medical test results is highly automatable via OCR, HL7/FHIR parsing, and direct EHR integration. Current AI systems can reliably extract numeric values and categorical results from lab reports and populate databases with >50% time savings and minimal quality degradation. |
| Task automatability | claude-sonnet-5 | 4/5 | Data entry from structured instrument outputs into LIS/EMR systems is largely automatable via instrument interfaces and middleware/OCR, meeting the time-saving threshold for most standardized tests, though some manual transcription of non-standard results remains. |
| Adoption barriers | claude-haiku-4-5-20251001 | 2/5 | While data entry is not inherently restricted by licensing, HIPAA compliance and EHR audit requirements create moderate friction around oversight and validation. However, no legal requirement mandates human data entry, and integration is increasingly standard in healthcare IT procurement. |
| Adoption barriers | claude-sonnet-5 | 2/5 | Regulatory frameworks (CLIA, CAP) require validated data handling and audit trails, but automated data capture is already standard practice and accepted, so barriers are moderate rather than strict human-only mandates. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 5/5 | Automated data entry via OCR and integration tools costs pennies per record; human entry at typical lab technician wages ($35–50k annual) costs dollars per record. AI is orders of magnitude cheaper for high-volume structured data. |
| Cost vs. human wage | claude-sonnet-5 | 4/5 | Once an LIS/middleware integration is installed, marginal cost per result entry is near zero compared to technologist time, though initial integration and validation costs are non-trivial. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 4/5 | Mature products (e.g., hospital IT systems with ML-powered data capture, RPA platforms) perform lab result entry at scale in production healthcare settings. Some error rates remain on unstructured or handwritten inputs, but mainstream EHR systems with automated ingestion are widely deployed. |
| Technical feasibility today | claude-sonnet-5 | 4/5 | Laboratory information systems (LIS) with bidirectional instrument interfaces are widely deployed in production labs today, automatically capturing and storing results without manual keystrokes for most analyzers. |
Analyze samples of biological material for chemical content or reaction.
41CI 25–56 · exposure 42 · augmentation 63 · importance 4.8/5 · click for rater detail
Analyze samples of biological material for chemical content or reaction.
41| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 4/5 | Large hospital systems and reference labs have rapidly adopted high-throughput automated analyzers and AI-assisted interpretation over the past decade, though smaller clinics and some specialized tests lag adoption. |
| Sector adoption velocity | claude-sonnet-5 | 2/5 | Healthcare and clinical labs are historically slower adopters of AI compared to fully digital sectors, with automation focused on instrumentation rather than end-to-end AI-driven interpretation. |
| Augmentation potential | claude-haiku-4-5-20251001 | 4/5 | AI tools for image analysis, pattern recognition in lab results, and anomaly detection meaningfully assist technologists in reviewing samples, flagging abnormalities, and prioritizing cases, substantially raising their output without removing the human from the loop. |
| Augmentation potential | claude-sonnet-5 | 3/5 | AI-assisted analytics and pattern recognition tools can help flag abnormal results or suggest interpretations, improving technologist efficiency, though the core physical/chemical analysis still requires hands-on execution. |
| Task automatability | claude-haiku-4-5-20251001 | 3/5 | Modern laboratory analyzers can autonomously perform routine chemical and immunoassay testing on standardized samples, but complex samples, troubleshooting, quality control decisions, and result interpretation often require human intervention, limiting time savings to roughly 50% of the full analytical workflow. |
| Task automatability | claude-sonnet-5 | 2/5 | Physical sample handling and much of the analytical chemistry work requires lab instrumentation and manual technique that AI software alone cannot perform; AI can assist with data interpretation but not the physical assay execution end-to-end. |
| Adoption barriers | claude-haiku-4-5-20251001 | 4/5 | Clinical laboratory testing is heavily regulated (CLIA in the US, ISO 15189 internationally) and requires certified technologists to validate results, ensure quality control, and bear responsibility for patient safety, creating a strong regulatory barrier to full automation without human oversight. |
| Adoption barriers | claude-sonnet-5 | 4/5 | Clinical lab testing is subject to CLIA certification, licensure requirements for technologists, and strict regulatory/quality oversight, creating strong legal barriers to full automation without certified human involvement. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 4/5 | Automated laboratory instruments have high capital costs but very low per-sample inference costs after amortization, making them substantially cheaper per test than manual technician labor over the instrument's lifetime. |
| Cost vs. human wage | claude-sonnet-5 | 2/5 | Lab automation equipment and skilled technologist oversight remain costly; while automated analyzers reduce marginal cost, they are capital-intensive and don't represent an order-of-magnitude AI cost advantage over trained technologists specifically for interpretive judgment. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 4/5 | Automated analyzers and AI-aided image recognition systems are deployed in clinical labs worldwide for high-volume sample analysis and preliminary result interpretation, though they typically require human validation and are constrained to predefined analytes and sample types. |
| Technical feasibility today | claude-sonnet-5 | 2/5 | Automated lab analyzers and LIS software exist and are widely deployed, but AI-driven interpretation of chemical/reaction results is still largely rule-based or human-reviewed rather than autonomous AI performing the full analysis reliably. |
Conduct chemical analysis of body fluids, including blood, urine, or spinal fluid, to determine presence of normal or abnormal components.
36CI 30–41 · exposure 42 · augmentation 75 · importance 4.8/5 · click for rater detail
Conduct chemical analysis of body fluids, including blood, urine, or spinal fluid, to determine presence of normal or abnormal components.
36| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 2/5 | Clinical laboratories have adopted automated instruments and AI-assisted interpretation tools incrementally, but true autonomous chemical analysis remains rare and confined to specific high-volume assays. Most labs maintain hybrid human-machine workflows rather than replacing technologists. |
| Sector adoption velocity | claude-sonnet-5 | 3/5 | Clinical laboratories have long adopted automated analyzers and LIS integration, but adoption of newer AI-driven diagnostic tools is more cautious and incremental due to regulatory oversight and validation requirements. |
| Augmentation potential | claude-haiku-4-5-20251001 | 4/5 | AI substantially augments technologists by automating result interpretation, flagging critical values, pattern matching against reference databases, and reducing manual report writing. These tools meaningfully increase technologist productivity while keeping the human responsible for validation and decision-making. |
| Augmentation potential | claude-sonnet-5 | 4/5 | AI and automated systems significantly augment technologists by flagging abnormal results, suggesting follow-up tests, and streamlining workflow, while humans remain responsible for validation and clinical judgment. |
| Task automatability | claude-haiku-4-5-20251001 | 2/5 | While AI can interpret lab results and flag abnormalities from existing data, the task requires physical specimen preparation, instrument operation, and quality control that current AI cannot perform end-to-end. AI assists in result interpretation but cannot replace the full workflow of sample handling, analysis execution, and validation. |
| Task automatability | claude-sonnet-5 | 3/5 | The actual chemical analysis is largely performed by automated laboratory analyzers already, but sample handling, quality control, troubleshooting, and result verification still require human technologists, so full end-to-end AI automation beyond current lab automation is limited. |
| Adoption barriers | claude-haiku-4-5-20251001 | 4/5 | Clinical laboratory testing is heavily regulated (CLIA, CAP) with explicit requirements for licensed personnel to perform and certify analyses. Chain-of-custody, quality assurance documentation, and legal liability for erroneous results create strong regulatory and liability barriers to full automation. |
| Adoption barriers | claude-sonnet-5 | 4/5 | Clinical lab testing is heavily regulated (CLIA, CAP accreditation) and requires licensed technologists to run, verify, and sign off on results, creating strong legal and liability barriers to full automation. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 2/5 | Current AI tools (LIS integration, result interpretation software) are moderately expensive to implement and maintain, while the core analysis still requires technologist labor for specimen handling and instrument operation. Cost savings are partial and do not yet reach parity with human labor for the complete task. |
| Cost vs. human wage | claude-sonnet-5 | 2/5 | Lab analyzers are expensive capital equipment requiring maintenance, reagents, and calibration by trained staff, so while throughput is high, the all-in cost per test is not dramatically cheaper than skilled labor once oversight is included. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 3/5 | AI-based laboratory analysis tools exist (e.g., automated flagging of results, pattern recognition in blood panels) and are deployed in some labs, but they operate narrowly on structured numerical data and require substantial human oversight. No current system reliably performs the full chemical analysis task autonomously. |
| Technical feasibility today | claude-sonnet-5 | 3/5 | Automated clinical chemistry analyzers are mature and widely deployed, but they are hardware-based lab automation rather than general AI systems, and result interpretation/exception handling still requires certified technologists. |
Analyze laboratory findings to check the accuracy of the results.
34CI 25–43 · exposure 33 · augmentation 75 · importance 4.8/5 · click for rater detail
Analyze laboratory findings to check the accuracy of the results.
34| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 2/5 | Adoption of AI-driven QC tools in clinical labs is still in early pilot phase; most labs continue manual verification or simple algorithmic flagging. Digital health IT adoption in labs is advancing, but AI-specific penetration remains limited and cautious. |
| Sector adoption velocity | claude-sonnet-5 | 2/5 | Healthcare and clinical labs are historically slow adopters of full automation for diagnostic decision tasks due to regulatory and safety concerns, though rule-based automated flagging is common. |
| Augmentation potential | claude-haiku-4-5-20251001 | 4/5 | AI can substantially assist technologists by automating repetitive flagging, highlighting out-of-range values, detecting statistical inconsistencies, and surfacing quality issues for human review. This reduces cognitive load and allows technologists to focus on complex judgment, directly raising task productivity. |
| Augmentation potential | claude-sonnet-5 | 4/5 | AI-based anomaly detection, delta checks, and pattern recognition tools significantly help technologists flag potential errors faster, improving throughput while humans retain final judgment. |
| Task automatability | claude-haiku-4-5-20251001 | 3/5 | Current AI can flag anomalies, detect patterns, and perform statistical validity checks on lab results, but cannot fully replace human judgment on clinical interpretation, sample quality assessment, or contextual patient factors. Partial automation of QC workflows could yield meaningful time savings with proper setup. |
| Task automatability | claude-sonnet-5 | 2/5 | Some quality-control checks (e.g., flagging outlier values, delta checks) can be automated via lab information systems, but comprehensive accuracy verification requires contextual clinical judgment and troubleshooting that current AI cannot fully replicate end-to-end. |
| Adoption barriers | claude-haiku-4-5-20251001 | 3/5 | Clinical laboratories face moderate adoption friction: regulatory (CLIA) requirements demand human sign-off on result release, accreditation standards require documented QC procedures, and liability for erroneous results creates organizational caution. However, no single barrier legally prohibits AI-assisted review, only supervised use. |
| Adoption barriers | claude-sonnet-5 | 4/5 | Clinical laboratory results verification is subject to regulatory requirements (e.g., CLIA) requiring qualified personnel sign-off, and errors carry significant patient safety and liability consequences. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 3/5 | Software licensing, integration into existing lab workflows, and required technologist oversight make AI-assisted QC roughly cost-neutral compared to traditional manual verification, with modest savings potential depending on deployment scale. |
| Cost vs. human wage | claude-sonnet-5 | 2/5 | Basic automated QC checks are cheap and already built into LIS software, but comprehensive AI review requiring clinical judgment still needs human oversight, keeping overall costs comparable to human-driven verification. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 2/5 | While AI-powered LIS (Laboratory Information System) anomaly detection and rule-based flagging exist in some labs, most systems lack the interpretive sophistication needed for reliable end-to-end accuracy verification. Deployed products are limited in scope and typically require significant human oversight of their flagging decisions. |
| Technical feasibility today | claude-sonnet-5 | 2/5 | Lab information systems and middleware have automated rule-based flagging for years, but true AI-driven interpretation of anomalous results in production clinical settings remains limited and narrow in scope. |
Collect and study blood samples to determine the number of cells, their morphology, or their blood group, blood type, or compatibility for transfusion purposes, using microscopic techniques.
29CI 25–32 · exposure 30 · augmentation 63 · importance 4.7/5 · click for rater detail
Collect and study blood samples to determine the number of cells, their morphology, or their blood group, blood type, or compatibility for transfusion purposes, using microscopic techniques.
29| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 2/5 | Laboratory automation adoption is moderate and incremental, focused on high-throughput analyzers rather than AI-driven microscopy review. Healthcare organizations are conservative with blood-safety automation; most labs are in pilot or early adoption phases for AI-assisted morphology, not production displacement. |
| Sector adoption velocity | claude-sonnet-5 | 3/5 | Clinical laboratories have adopted automated analyzers and digital imaging tools substantially, but full AI-driven interpretation and blood banking decisions are still adopted cautiously due to regulatory and safety concerns. |
| Augmentation potential | claude-haiku-4-5-20251001 | 3/5 | AI-powered image analysis can assist technologists by pre-screening slides, flagging abnormal cells, and suggesting cell counts, reducing review time and cognitive load. However, the human technologist must validate findings and take responsibility for accuracy, so AI augmentation is meaningful but not transformative in current practice. |
| Augmentation potential | claude-sonnet-5 | 4/5 | AI-assisted digital microscopy and automated analyzers significantly speed up cell counting and flagging abnormalities, letting technologists focus on verification and complex morphology review, meaningfully raising productivity while humans remain responsible for final determinations. |
| Task automatability | claude-haiku-4-5-20251001 | 2/5 | While AI-powered image analysis can assist in cell counting and morphology assessment from microscopy images, the task requires specimen preparation, slide handling, and physical blood collection—only the analytical portion is automatable. End-to-end automation with 50% time savings remains unrealistic due to the manual sample handling, quality control, and validation steps that humans must oversee. |
| Task automatability | claude-sonnet-5 | 2/5 | Physical blood sample collection and much of manual microscopic analysis still require human dexterity and judgment; automated hematology analyzers assist but full end-to-end automation including phlebotomy and edge-case interpretation is not yet achievable at the 50% threshold across the whole task. |
| Adoption barriers | claude-haiku-4-5-20251001 | 4/5 | Blood typing and transfusion compatibility determination carry high regulatory oversight (CLIA, FDA, blood bank standards) and carry significant liability if errors occur. Clinical laboratories require licensed technologists to perform and validate these tests, and regulatory bodies mandate documented human responsibility for transfusion-critical decisions. |
| Adoption barriers | claude-sonnet-5 | 4/5 | Clinical laboratory testing is subject to CLIA and other regulatory frameworks requiring certified personnel to perform and verify results, especially for transfusion compatibility, where errors carry high liability and patient safety risk. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 2/5 | Current AI image analysis tools require significant capital investment, integration into lab workflows, and human oversight for validation and error-checking. The loaded cost of a trained laboratory technologist remains competitive, especially when factoring in the need for human sign-off and medico-legal liability. |
| Cost vs. human wage | claude-sonnet-5 | 2/5 | Lab automation equipment has high capital and maintenance costs and still requires skilled technologist oversight, so total cost savings versus a human technologist are moderate rather than order-of-magnitude cheaper for the full task. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 2/5 | AI systems exist for cell classification and counting in research and pilot settings (e.g., image analysis tools), but deployed products in clinical laboratories for full blood cell differential or transfusion compatibility assessment remain limited. Most labs still rely on analyzers paired with human microscopy review rather than fully autonomous AI systems. |
| Technical feasibility today | claude-sonnet-5 | 3/5 | Automated hematology analyzers and digital morphology systems (e.g., CellaVision) are deployed in many labs for cell counting and flagging abnormal cells, but complex crossmatching, blood typing confirmation, and ambiguous morphology review still require certified technologists. |
Establish or monitor quality assurance programs or activities to ensure the accuracy of laboratory results.
25CI 25–25 · exposure 25 · augmentation 63 · importance 4.7/5 · click for rater detail
Establish or monitor quality assurance programs or activities to ensure the accuracy of laboratory results.
25| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 2/5 | While healthcare digitization is advancing, QA program oversight remains largely manual and technologist-driven in most labs. Adoption of AI-assisted QA tools is emerging but slow; most labs still rely on incumbent LIS vendors with incremental improvements rather than AI-driven transformation. |
| Sector adoption velocity | claude-sonnet-5 | 2/5 | Healthcare and clinical labs are historically slow adopters of full AI automation due to regulatory certification requirements, though statistical QC software has been standard for decades. |
| Augmentation potential | claude-haiku-4-5-20251001 | 3/5 | AI can meaningfully assist by automating routine monitoring of control samples, detecting statistical trends, and generating QA reports, which would help technologists focus on exception handling and program refinement. However, the task is not fundamentally transformed by AI assistance since human judgment on protocol changes and compliance remains central. |
| Augmentation potential | claude-sonnet-5 | 4/5 | AI-driven statistical process control and anomaly detection tools significantly help technologists monitor trends and flag out-of-control results faster than manual review, while the human retains responsibility for QA decisions. |
| Task automatability | claude-haiku-4-5-20251001 | 2/5 | While AI can assist with data analysis, trend detection, and flagging anomalies in test results, establishing and monitoring comprehensive quality assurance programs requires human judgment on protocol design, regulatory interpretation, and organizational decision-making that current systems cannot fully automate. The task involves strategic oversight and accountability that remains fundamentally human. |
| Task automatability | claude-sonnet-5 | 2/5 | Quality assurance in a clinical lab requires designing protocols, interpreting deviations, and making judgment calls about corrective actions that current AI cannot reliably perform end-to-end.<br>AI can assist with statistical monitoring but cannot establish or oversee a full QA program autonomously. |
| Adoption barriers | claude-haiku-4-5-20251001 | 4/5 | Laboratory QA programs fall under CLIA, CAP, and ISO standards that legally require qualified laboratory personnel to establish and sign off on quality procedures. The regulatory burden and professional licensure requirements create substantial friction against full automation or delegation to unsupervised AI systems. |
| Adoption barriers | claude-sonnet-5 | 4/5 | Clinical labs operate under strict regulatory frameworks (CLIA, CAP, ISO 15189) requiring qualified personnel to establish and sign off on QA programs, creating strong legal and liability barriers to full automation. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 2/5 | AI tooling for QA monitoring (software, infrastructure, oversight) is comparable to or exceeds the marginal cost of routine technologist oversight when accounting for integration, calibration, and required human review of automated decisions. The task's criticality demands human sign-off, negating pure cost displacement. |
| Cost vs. human wage | claude-sonnet-5 | 2/5 | QC software is relatively cheap to run but still requires trained technologists to interpret results, investigate failures, and maintain compliance, so overall cost savings versus human oversight are modest. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 2/5 | Products exist for automated result validation and anomaly detection (e.g., LIS software with built-in QA rules), but these tools require human configuration, interpretation, and response. No deployed system independently manages entire QA programs; current tools operate as aids within human-directed frameworks rather than autonomous performers. |
| Technical feasibility today | claude-sonnet-5 | 2/5 | Some laboratory information systems include automated QC flagging (e.g., Westgard rules, Levey-Jennings charts) but these are decision-support tools, not autonomous QA program managers.<br>No deployed product independently establishes or runs a full QA program without technologist oversight. |
Provide technical information about test results to physicians, family members, or researchers.
25CI 25–25 · exposure 25 · augmentation 63 · importance 4.3/5 · click for rater detail
Provide technical information about test results to physicians, family members, or researchers.
25| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 2/5 | Adoption in clinical labs remains slow; most organizations use AI only for drafting summaries or triage, with humans retaining final responsibility. Regulatory caution and liability concerns in healthcare sectors slow deployment of autonomous result communication relative to other information work. |
| Sector adoption velocity | claude-sonnet-5 | 2/5 | Healthcare/clinical lab settings show cautious AI adoption due to regulatory and safety concerns, with most current use limited to back-office or diagnostic support rather than patient-facing communication. |
| Augmentation potential | claude-haiku-4-5-20251001 | 3/5 | AI can usefully assist technologists by drafting plain-language explanations, organizing results, or suggesting communication templates tailored to recipient type. Such tools raise efficiency in the explanation workflow, but the technologist must remain in control for accuracy, tone, and legal accountability. |
| Augmentation potential | claude-sonnet-5 | 4/5 | AI can help technologists draft clear explanations, summarize data trends, and prepare talking points, meaningfully speeding up communication tasks while the human remains responsible for accuracy and delivery. |
| Task automatability | claude-haiku-4-5-20251001 | 2/5 | Current AI can draft or summarize test result explanations, but communicating nuanced clinical findings to diverse audiences (physicians, families, researchers) requires contextual judgment, empathy, and liability responsibility that AI cannot reliably handle end-to-end today. A technologist must verify accuracy and adjust tone/depth per recipient—tasks requiring human expertise. |
| Task automatability | claude-sonnet-5 | 2/5 | Explaining and contextualizing lab results for physicians or families requires clinical judgment, handling of ambiguous or abnormal findings, and interpersonal communication that current AI cannot reliably replace end-to-end.' |
| Adoption barriers | claude-haiku-4-5-20251001 | 4/5 | Strong legal and regulatory barriers apply: Clinical Laboratory Improvement Amendments (CLIA) and medical liability law typically require a licensed individual to verify and sign off on communicated test results. Family communications and physician consultations carry liability risk that prevents full AI delegation. |
| Adoption barriers | claude-sonnet-5 | 4/5 | Clinical labs are regulated (CLIA), and communicating test results, especially critical values, often requires a qualified professional to interpret and relay information, creating strong liability and regulatory barriers. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 2/5 | Even where AI tools exist (chatbots, summarization APIs), they require oversight by qualified technologists or clinicians, negating most cost savings. Integration into EHR systems and regulatory compliance add overhead; the human cannot be removed from the loop due to liability and accuracy requirements. |
| Cost vs. human wage | claude-sonnet-5 | 2/5 | AI could cheaply draft summaries, but human oversight, verification, and liability concerns keep effective all-in costs closer to human costs for this communication task. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 2/5 | No deployed product reliably performs autonomous clinical result communication to patients or physicians at scale. LLM-based systems can generate explanations but lack verification mechanisms, legal accountability, and integration with actual lab workflows. Pilot systems exist but are not production-ready in regulated clinical settings. |
| Technical feasibility today | claude-sonnet-5 | 2/5 | Some AI tools can generate result summaries or draft explanations, but no deployed product independently communicates technical lab findings to physicians or families as a substitute for a technologist. |
Operate, calibrate, or maintain equipment used in quantitative or qualitative analysis, such as spectrophotometers, calorimeters, flame photometers, or computer-controlled analyzers.
23CI 21–25 · exposure 25 · augmentation 50 · importance 4.7/5 · click for rater detail
Operate, calibrate, or maintain equipment used in quantitative or qualitative analysis, such as spectrophotometers, calorimeters, flame photometers, or computer-controlled analyzers.
23| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 2/5 | Laboratory settings remain relatively conservative in automation adoption; while some large hospital labs use integrated analyzers, displacement of technician work through AI-driven equipment maintenance and calibration has not achieved meaningful production-level adoption in typical settings. |
| Sector adoption velocity | claude-sonnet-5 | 2/5 | Clinical laboratories are moderately digitized but physical equipment maintenance tasks lag behind software-based diagnostic AI adoption; automation here remains limited to embedded device firmware rather than agentic AI systems. |
| Augmentation potential | claude-haiku-4-5-20251001 | 3/5 | AI can assist technicians by monitoring analyzer performance, alerting to drift or required maintenance, and helping interpret quality control data, but human judgment and hands-on skill remain central to troubleshooting and equipment calibration, limiting the transformative potential. |
| Augmentation potential | claude-sonnet-5 | 3/5 | Modern analyzers already include software that assists with calibration diagnostics, error flagging, and quality control tracking, meaningfully aiding technologists without replacing their physical role. |
| Task automatability | claude-haiku-4-5-20251001 | 2/5 | While AI can assist with some aspects like data analysis and alarm monitoring, the physical operations of equipment calibration and maintenance (handling samples, adjusting instruments, troubleshooting hardware) require hands-on intervention that current robotics in lab settings cannot reliably automate end-to-end. The task involves too much variability in equipment types and failure modes for a 50% time-saving threshold. |
| Task automatability | claude-sonnet-5 | 2/5 | Physical operation, calibration, and maintenance of lab equipment require hands-on manipulation, physical dexterity, and troubleshooting that current AI cannot perform end-to-end; software-side calibration checks can be assisted but not fully automated. |
| Adoption barriers | claude-haiku-4-5-20251001 | 4/5 | Regulatory requirements (CLIA, CAP) and quality assurance standards mandate that calibration and maintenance procedures be performed and documented by qualified personnel, often with explicit sign-off requirements. Liability for incorrect calibration affecting patient results creates legal barriers to full automation. |
| Adoption barriers | claude-sonnet-5 | 4/5 | Clinical lab equipment operation is subject to regulatory oversight (CLIA, CAP accreditation) requiring qualified personnel to perform and verify calibration/maintenance, creating strong compliance and liability barriers. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 2/5 | The cost of specialized robotics, computer vision integration, and AI oversight to handle diverse lab equipment types would exceed the loaded wage of a laboratory technician. Current AI systems cannot offer order-of-magnitude savings for this hands-on, equipment-specific work. |
| Cost vs. human wage | claude-sonnet-5 | 1/5 | Physical calibration and maintenance require human presence and manual dexterity; AI cannot substitute for the labor, so there is no cost-saving substitution available today. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 2/5 | No deployed product reliably performs the full spectrum of equipment operation, calibration, and maintenance autonomously in production lab environments. While software can monitor some analyzer outputs, the calibration procedures and physical maintenance still depend on trained human technicians; research systems exist but lack real-world deployment at scale. |
| Technical feasibility today | claude-sonnet-5 | 2/5 | Some analyzers have built-in automated calibration routines and diagnostics, but full equipment maintenance and operation still relies heavily on trained technologists physically present; no deployed AI product independently operates/maintains this equipment. |
Cultivate, isolate, or assist in identifying microbial organisms or perform various tests on these microorganisms.
23CI 21–25 · exposure 25 · augmentation 50 · importance 4.5/5 · click for rater detail
Cultivate, isolate, or assist in identifying microbial organisms or perform various tests on these microorganisms.
23| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 2/5 | Adoption of AI-assisted image analysis in clinical labs is emerging but slow and concentrated in large institutions; most microbiology workflows remain manual. The physical and regulatory constraints of clinical lab environments limit rapid scaling of autonomous microbial processing. |
| Sector adoption velocity | claude-sonnet-5 | 2/5 | Clinical laboratories are moderate adopters of automation (e.g., automated plate streakers, digital imaging) but full AI-driven identification workflows remain in pilot or narrow deployment stages, not widespread displacement. |
| Augmentation potential | claude-haiku-4-5-20251001 | 3/5 | AI-powered microscopy image analysis and organism identification databases can meaningfully assist technologists in confirming diagnoses and reducing review time, but the core cultivation and isolation work still requires human expertise and hands-on execution. Assistance is real but limited to portions of the workflow. |
| Augmentation potential | claude-sonnet-5 | 3/5 | AI-assisted imaging and pattern-recognition tools can help technologists flag colony morphology or suggest species matches, improving throughput and accuracy while the technologist remains responsible for confirmation. |
| Task automatability | claude-haiku-4-5-20251001 | 2/5 | While AI can assist in microscopy image analysis and organism identification via computer vision, the hands-on cultivation, isolation, and physical manipulation of microbial cultures require human execution today. Current systems cannot independently perform the wet-lab work or achieve the 50% time-saving threshold for the full end-to-end task. |
| Task automatability | claude-sonnet-5 | 2/5 | Physical culturing, isolation, and hands-on microbial testing require manipulation of specimens and equipment that current AI cannot perform; only interpretive/analytic sub-steps are automatable. |
| Adoption barriers | claude-haiku-4-5-20251001 | 4/5 | Clinical laboratory work is heavily regulated (CLIA, CAP standards) and typically requires certified laboratory technologists to perform or oversee microbial identification and testing. Liability concerns around misidentification, plus regulatory requirements for licensed personnel, create substantial barriers to full automation. |
| Adoption barriers | claude-sonnet-5 | 4/5 | Clinical microbiology testing is subject to CLIA/lab accreditation requirements and typically requires certified medical technologists to perform and validate results, creating strong regulatory and liability barriers. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 1/5 | Current AI tools for microbiology require significant human oversight, integration, and validation, while the equipment and labor for hands-on culture work remain essential. The all-in cost of AI assistance plus human labor exceeds the cost of a trained technologist performing the task directly. |
| Cost vs. human wage | claude-sonnet-5 | 2/5 | Automated microbiology analyzers and AI image-analysis tools have high capital and integration costs, offsetting labor savings; overall cost is comparable to or higher than technologist labor for full task scope. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 2/5 | Deployed products exist for image-based organism identification (e.g., pathology AI), but these cover only one component and require expert human validation. Autonomous cultivation and isolation systems remain largely research-stage; no mature, production-scale systems reliably execute the full microbial workflow without human intervention. |
| Technical feasibility today | claude-sonnet-5 | 2/5 | Some automated culture-reading and AI-assisted colony identification systems (e.g., MALDI-TOF interpretation aids, digital microbiology platforms) exist in production but cover only narrow parts of the workflow, not the full cultivation/isolation process. |
Develop, standardize, evaluate, or modify procedures, techniques, or tests used in the analysis of specimens or in medical laboratory experiments.
23CI 20–25 · exposure 20 · augmentation 50 · importance 4.3/5 · click for rater detail
Develop, standardize, evaluate, or modify procedures, techniques, or tests used in the analysis of specimens or in medical laboratory experiments.
23| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 2/5 | Laboratory and clinical settings are highly regulated and conservative environments where procedure changes require extensive validation and regulatory review. Adoption of AI-driven procedure development is slow and primarily limited to large research institutions, with strong institutional resistance to replacing human expertise in critical validation roles. |
| Sector adoption velocity | claude-sonnet-5 | 2/5 | Clinical laboratory settings adopt AI cautiously due to regulatory scrutiny and patient safety concerns, with pilots for specific analytic tasks but slow uptake for procedure development itself. |
| Augmentation potential | claude-haiku-4-5-20251001 | 3/5 | AI can meaningfully assist by accelerating literature synthesis, helping optimize experimental parameters through data analysis, and automating documentation of procedure changes. However, the augmentation is limited to supporting phases rather than transforming the core experimental design and hands-on validation work. |
| Augmentation potential | claude-sonnet-5 | 3/5 | AI can help technologists draft protocols, analyze validation data, and search relevant literature or regulations, providing useful support without replacing the core experimental and judgment work. |
| Task automatability | claude-haiku-4-5-20251001 | 2/5 | While AI can assist with literature review and procedure documentation, the core task of developing and validating novel laboratory procedures requires hands-on experimental iteration, judgment about specimen handling, and domain expertise that current AI systems cannot fully replicate. The task involves live experimentation and technical validation that cannot be compressed by 50% with AI working autonomously. |
| Task automatability | claude-sonnet-5 | 2/5 | This involves experimental design, validation studies, and hands-on lab work that current AI cannot perform end-to-end; AI can assist with literature review, statistical analysis, and drafting protocols but cannot conduct wet-lab validation or judgment-based standardization independently. |
| Adoption barriers | claude-haiku-4-5-20251001 | 4/5 | Laboratory procedure development and validation typically must be performed or directly supervised by credentialed laboratory professionals (MLT, PhD) due to regulatory standards (CLIA, CAP) and quality assurance requirements. Legal and compliance responsibility for procedure validation creates a hard barrier to autonomous AI substitution. |
| Adoption barriers | claude-sonnet-5 | 4/5 | Clinical lab tests are subject to regulatory validation (CLIA, FDA, accreditation standards) requiring qualified personnel to develop and sign off on procedures, creating substantial compliance and liability barriers. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 2/5 | AI tools for research support (literature mining, data analysis) are relatively inexpensive, but they cannot replace the technologist's salary for the core development and validation work. The human expert remains essential and the cost of AI augmentation is a small fraction of the human labor cost. |
| Cost vs. human wage | claude-sonnet-5 | 2/5 | AI tools can reduce time spent on literature synthesis or documentation, but the core work still requires skilled technologist labor and lab resources, so overall cost savings are modest rather than transformative. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 2/5 | No deployed AI product reliably develops, standardizes, or evaluates laboratory procedures end-to-end. AI tools can support research and documentation but cannot independently conduct wet-lab experiments, troubleshoot equipment failures, or make the iterative protocol adjustments that characterize this work. |
| Technical feasibility today | claude-sonnet-5 | 1/5 | No deployed product autonomously develops or validates clinical lab testing procedures; this remains a highly specialized, research-stage application requiring expert oversight and physical experimentation. |
Obtain, cut, stain, and mount biological material on slides for microscopic study and diagnosis, following standard laboratory procedures.
21CI 16–25 · exposure 20 · augmentation 50 · importance 4.5/5 · click for rater detail
Obtain, cut, stain, and mount biological material on slides for microscopic study and diagnosis, following standard laboratory procedures.
21| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 2/5 | While major hospitals and reference labs have adopted partial automation (stainers, some mounting), widespread adoption of full end-to-end specimen preparation automation remains limited. Small labs and regional centers continue manual processes due to cost and regulatory conservatism. |
| Sector adoption velocity | claude-sonnet-5 | 2/5 | While some lab automation (e.g., automated stainers, tissue processors) exists and is adopted, AI-driven end-to-end automation of this specific task is not widespread; healthcare lab settings adopt digitization slowly relative to pure information sectors. |
| Augmentation potential | claude-haiku-4-5-20251001 | 3/5 | AI-assisted image analysis and computer-aided diagnosis systems can help technologists and pathologists interpret slides more accurately, and semi-automated staining/mounting equipment augments productivity on routine samples. However, the physical specimen preparation phases offer limited augmentation potential. |
| Augmentation potential | claude-sonnet-5 | 3/5 | AI can assist with image analysis and quality control after slides are prepared, and automated staining machines aid consistency, but the core cutting/mounting/staining process itself sees only modest AI-driven productivity gains. |
| Task automatability | claude-haiku-4-5-20251001 | 2/5 | While staining and mounting are routine procedural steps that could be partially automated, obtaining and cutting biological material require spatial reasoning, tactile feedback, and judgment about tissue quality that current robots struggle with reliably. End-to-end automation achieving 50% time savings at equal quality is not yet demonstrated at scale. |
| Task automatability | claude-sonnet-5 | 2/5 | Physical specimen handling, cutting, staining, and mounting require manual dexterity and precise physical manipulation of biological samples that current AI systems cannot perform; only image analysis after slide preparation is automatable, not the preparation itself.The core task is a physical/manual laboratory procedure. |
| Adoption barriers | claude-haiku-4-5-20251001 | 4/5 | Clinical laboratory work is heavily regulated (CLIA in the US, ISO 15189 internationally), and slides used for diagnosis typically require documented human review and sign-off. Liability for diagnostic errors creates strong friction against full automation without human oversight. |
| Adoption barriers | claude-sonnet-5 | 4/5 | Clinical laboratory work is subject to CLIA regulations and requires certified personnel to perform specimen preparation for diagnostic purposes, with liability concerns around diagnostic accuracy creating strong barriers to full automation. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 2/5 | Partial automation (staining/mounting machines) exists but capital costs and integration overhead remain high relative to technician wages. Complete end-to-end automation would require expensive robotic systems, making the all-in cost comparable to or higher than skilled human labor. |
| Cost vs. human wage | claude-sonnet-5 | 1/5 | There is no viable AI substitute for the physical specimen preparation process, so cost comparison favors the human entirely since robotic automation for this specific multi-step physical task is not commercially deployed at scale. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 2/5 | Some staining and mounting equipment is semi-automated in labs, but fully autonomous slide preparation from raw specimen to diagnosis-ready slide lacks reliable deployed systems. Existing automation handles narrow, standardized protocols but fails on variability in specimen type, size, and condition. |
| Technical feasibility today | claude-sonnet-5 | 1/5 | No deployed AI product exists that can obtain, cut, stain, and mount biological specimens; this remains entirely a manual laboratory technique performed by trained technologists using specialized equipment like microtomes and staining baths. |
Set up, clean, and maintain laboratory equipment.
17CI 13–21 · exposure 8 · augmentation 38 · importance 4.7/5 · click for rater detail
Set up, clean, and maintain laboratory equipment.
17| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 2/5 | Most clinical laboratories remain relatively slow to adopt automation for routine maintenance tasks; adoption is largely limited to large medical centers and specialized research facilities, with widespread small and mid-size labs continuing manual maintenance. |
| Sector adoption velocity | claude-sonnet-5 | 2/5 | Clinical lab settings are moderately digitized for data/analysis but physical equipment upkeep remains low-tech and slow to adopt automation beyond fixed robotic analyzers. |
| Augmentation potential | claude-haiku-4-5-20251001 | 3/5 | AI can assist technologists by scheduling maintenance reminders, logging equipment performance data, and flagging calibration drift, which improves compliance and reduces oversight burden, though the core manual work remains human-performed. |
| Augmentation potential | claude-sonnet-5 | 2/5 | AI can assist with maintenance scheduling, predictive alerts, or digital logs, but offers minimal help with the actual physical setup and cleaning work. |
| Task automatability | claude-haiku-4-5-20251001 | 2/5 | While some equipment maintenance steps (e.g., calibration logging, scheduling) could be partially automated, the physical setup, cleaning, and hands-on maintenance of delicate laboratory instruments requires manual dexterity and real-time problem-solving that current AI/robotics cannot reliably perform end-to-end at 50% time savings. |
| Task automatability | claude-sonnet-5 | 1/5 | This is a physical, hands-on task involving handling instruments, calibration tools, and cleaning materials that current AI systems cannot perform without robotic embodiment.' |
| Adoption barriers | claude-haiku-4-5-20251001 | 3/5 | Regulatory requirements (e.g., CLIA, equipment-specific certifications) and organizational protocols often mandate human sign-off and accountability for equipment maintenance, creating some friction, though these are primarily procedural rather than absolute legal prohibitions on automation. |
| Adoption barriers | claude-sonnet-5 | 3/5 | While not explicitly licensed work, lab equipment maintenance often follows regulatory/quality protocols (CLIA, accreditation standards) requiring trained personnel, creating moderate organizational and compliance friction. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 1/5 | Specialized robotic systems capable of laboratory equipment maintenance are capital-intensive and require ongoing technical support, making them substantially more expensive than the hourly wage of a laboratory technologist for most settings. |
| Cost vs. human wage | claude-sonnet-5 | 1/5 | There is no viable AI substitute performing this physical task, so AI cost is effectively infinite relative to human labor for this specific action. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 1/5 | No deployed production systems today reliably perform the full suite of laboratory equipment setup, cleaning, and maintenance tasks; specialized lab robots exist for narrow, controlled tasks but not general-purpose maintenance. |
| Technical feasibility today | claude-sonnet-5 | 1/5 | No deployed product autonomously sets up, cleans, and maintains lab equipment; this remains a manual technician responsibility in real labs today. |
Harvest cell cultures at optimum time, based on knowledge of cell cycle differences and culture conditions.
16CI 7–25 · exposure 13 · augmentation 38 · importance 4.0/5 · click for rater detail
Harvest cell cultures at optimum time, based on knowledge of cell cycle differences and culture conditions.
16| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 2/5 | Adoption of AI for cell culture monitoring is nascent outside research labs and specialized biotech firms. Most clinical and hospital laboratories still rely on manual microscopy and technologist judgment; digitized monitoring with AI scoring remains in early pilots, not routine production. |
| Sector adoption velocity | claude-sonnet-5 | 2/5 | Clinical laboratory settings have moderate digitization for data analysis but physical wet-lab procedures like cell harvesting remain largely unautomated and adopt robotics/AI slowly due to cost and validation requirements. |
| Augmentation potential | claude-haiku-4-5-20251001 | 3/5 | AI-powered image analysis can assist technologists by flagging cultures approaching confluence or detecting contamination, reducing manual microscopy time. However, the technologist remains the decision-maker and performs the harvest; assistance is meaningful but partial, not transformative of the full task. |
| Augmentation potential | claude-sonnet-5 | 2/5 | AI can assist with predictive modeling of optimal harvest timing based on growth curve data or imaging analysis, but the physical execution and moment-to-moment judgment remain human-driven with limited current AI tool integration. |
| Task automatability | claude-haiku-4-5-20251001 | 2/5 | Cell culture harvesting requires real-time visual assessment of culture conditions, microscopic examination of cell morphology, and timing judgment based on subtle biological cues. While AI can support image analysis of cultures, the full end-to-end decision—when to harvest—remains dependent on embodied laboratory work and nuanced judgment that current systems cannot reliably automate at production scale. |
| Task automatability | claude-sonnet-5 | 1/5 | This is a hands-on physical laboratory task requiring manual manipulation of biological samples and real-time judgment about culture timing; no AI system can physically harvest cells or replace this manual bench work today. |
| Adoption barriers | claude-haiku-4-5-20251001 | 4/5 | Laboratory automation and cell culture work fall under strict regulatory frameworks (FDA, GLP, institutional biosafety committees). Most jurisdictions require a licensed clinical laboratory technologist or supervisor to validate and sign off on culture viability and harvest timing decisions; autonomous AI cannot legally substitute. |
| Adoption barriers | claude-sonnet-5 | 4/5 | Requires certified laboratory technologist training and hands-on skill; errors in timing affect diagnostic/research validity and patient safety in clinical contexts, with regulatory and accreditation oversight of lab procedures. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 2/5 | Current AI imaging and analysis tools require significant infrastructure, model training on lab-specific cultures, and human oversight to execute safely. The cost of these systems plus integration and technologist supervision remains comparable to or exceeds the cost of technologist time for routine harvesting. |
| Cost vs. human wage | claude-sonnet-5 | 1/5 | AI cannot perform the physical harvesting step at all, so there is no viable AI cost comparison—human labor is currently the only option. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 2/5 | AI image analysis tools exist for cell culture monitoring, but no deployed product reliably performs autonomous harvesting decisions in real laboratory settings. Published systems are research-stage; production use requires human technologists to validate timing and initiate harvest, not AI acting independently. |
| Technical feasibility today | claude-sonnet-5 | 1/5 | No deployed product performs physical cell culture harvesting; this remains a manual wet-lab technique requiring human dexterity and microscopic assessment. |
Select and prepare specimens and media for cell cultures, using aseptic technique and knowledge of medium components and cell requirements.
15CI 5–25 · exposure 13 · augmentation 38 · importance 4.6/5 · click for rater detail
Select and prepare specimens and media for cell cultures, using aseptic technique and knowledge of medium components and cell requirements.
15| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 2/5 | Adoption of full automation in clinical lab specimen preparation is slow, concentrated in large reference labs and research centers. Most hospital and clinic labs still rely on human technologists for routine specimen and media preparation due to capital costs, regulatory caution, and specimen-type variability. |
| Sector adoption velocity | claude-sonnet-5 | 1/5 | Clinical laboratory specimen handling remains a physically-mediated, highly regulated process with minimal AI/robotic adoption for this specific manual task in real-world lab settings. |
| Augmentation potential | claude-haiku-4-5-20251001 | 3/5 | AI-assisted scheduling of specimen workflow, media component verification against cell type requirements, and process documentation can improve technologist efficiency and reduce errors. However, the core manual aseptic techniques remain human-dependent, limiting augmentation to planning and oversight roles. |
| Augmentation potential | claude-sonnet-5 | 2/5 | AI can assist with protocol lookup, documentation, and some scheduling/tracking of media components, but offers minimal help with the core physical and aseptic execution of the task. |
| Task automatability | claude-haiku-4-5-20251001 | 2/5 | While specimen selection logic and media preparation steps are theoretically automatable, the task critically depends on aseptic technique—a physical manipulation skill requiring real-time sensorimotor control and contamination prevention that current AI systems cannot reliably execute. Robotic arms exist but integration into lab workflows remains narrow and specialized. |
| Task automatability | claude-sonnet-5 | 1/5 | This is a hands-on physical laboratory task requiring manual pipetting, aseptic manipulation, and physical media preparation that current AI systems cannot perform without robotic embodiment.wraps |
| Adoption barriers | claude-haiku-4-5-20251001 | 4/5 | Clinical laboratory work is heavily regulated (CLIA, CAP) and relies on validated, documented procedures and technologist sign-off for specimen integrity and quality assurance. Liability and regulatory requirements demand human accountability, and automation of aseptic technique itself faces validation barriers that delay deployment. |
| Adoption barriers | claude-sonnet-5 | 4/5 | Clinical lab work is subject to CLIA and accreditation requirements, requiring certified personnel to handle specimens and maintain quality/chain-of-custody, creating strong regulatory and liability barriers. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 2/5 | Specialized laboratory robotics and integration infrastructure are expensive upfront, and aseptic technique errors carry high material and regulatory costs. For small-to-medium labs and low-volume specimen types, human technologists remain more cost-effective than deploying and maintaining full automation. |
| Cost vs. human wage | claude-sonnet-5 | 1/5 | There is no viable AI-only substitute; any automation would require expensive specialized robotics/lab automation hardware costing far more than a technologist's labor for this task. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 2/5 | Laboratory automation platforms can assist with some preparation steps (mixing media, aliquoting), but end-to-end specimen selection, preparation, and aseptic culture initiation under variable conditions lacks reliable production-grade AI deployment in typical clinical labs. Most existing systems handle only constrained, high-volume scenarios. |
| Technical feasibility today | claude-sonnet-5 | 1/5 | No deployed AI product performs physical specimen selection or aseptic media preparation; lab automation robots exist but are narrow, expensive, and not AI-driven decision systems for this specific task. |
Supervise, train, or direct lab assistants, medical and clinical laboratory technicians or technologists, or other medical laboratory workers engaged in laboratory testing.
11CI 5–16 · exposure 8 · augmentation 50 · importance 4.7/5 · click for rater detail
Supervise, train, or direct lab assistants, medical and clinical laboratory technicians or technologists, or other medical laboratory workers engaged in laboratory testing.
11| Dimension | Model | Rating | Rationale |
|---|---|---|---|
| Sector adoption velocity | claude-haiku-4-5-20251001 | 1/5 | Healthcare and laboratory settings adopt automation cautiously and unevenly; supervisory automation is not a focus of current adoption, and organizational culture strongly favors human leadership and accountability in clinical environments. |
| Sector adoption velocity | claude-sonnet-5 | 2/5 | Healthcare and clinical lab settings are moderate adopters of AI for diagnostics but slow to adopt AI for personnel management and training functions. |
| Augmentation potential | claude-haiku-4-5-20251001 | 3/5 | AI could meaningfully assist supervisors by automating training-record management, flagging quality anomalies for review, or scheduling optimization, raising supervisor efficiency in administrative tasks while the human retains full responsibility for personnel decisions and team development. |
| Augmentation potential | claude-sonnet-5 | 3/5 | AI can assist with training materials, competency tracking, scheduling, and performance analytics, but the core supervisory and mentoring relationship remains human-driven. |
| Task automatability | claude-haiku-4-5-20251001 | 2/5 | This task involves real-time personnel management, mentoring, and adaptive decision-making in a dynamic laboratory environment. While AI could assist with documentation and scheduling, the interpersonal, evaluative, and corrective feedback components require human judgment and cannot be fully automated to meet the 50% time-saving threshold. |
| Task automatability | claude-sonnet-5 | 1/5 | Supervising, training, and directing staff requires interpersonal leadership, judgment about individual competency, and real-time management that AI cannot perform end-to-end today.'}, |
| Adoption barriers | claude-haiku-4-5-20251001 | 4/5 | Strong regulatory and organizational barriers exist: laboratory directors and supervisors often carry formal credentialing requirements, professional responsibility, and liability for quality assurance. Healthcare settings also prioritize human judgment for personnel decisions and compliance oversight. |
| Adoption barriers | claude-sonnet-5 | 4/5 | Lab supervision often requires credentialed personnel (e.g., certified technologists) with legal responsibility for quality control and staff competency assessment, creating strong regulatory and liability barriers. |
| Cost vs. human wage | claude-haiku-4-5-20251001 | 1/5 | Supervisory and training labor is knowledge-intensive and relationship-dependent; AI systems cannot yet match the cost-effectiveness of a human supervisor when factoring in oversight, liability, and the quality of mentoring required. |
| Cost vs. human wage | claude-sonnet-5 | 1/5 | There is no AI substitute performing this supervisory role, so cost comparison favors the human by default. |
| Technical feasibility today | claude-haiku-4-5-20251001 | 1/5 | No deployed AI product reliably performs supervisory roles, performance evaluation, or personnel training in laboratory settings at production scale. This requires contextual judgment about individual competencies and immediate responsiveness to team needs that current systems cannot handle autonomously. |
| Technical feasibility today | claude-sonnet-5 | 1/5 | No deployed product manages or supervises human laboratory staff; this remains purely a human management function. |
Related occupations — Healthcare Practitioners & Technical
How to read this
A high substitution score does not mean this job disappears — it means a large share of its current tasks face replacement pressure, so the mix of tasks is likely to change. High augmentation alongside substitution typically means the occupation reorganizes around the protected tasks. Wide confidence intervals mean the rater panel disagreed: treat those scores as open questions, not verdicts.
What would change this score
New model capabilities (automatability, feasibility), falling inference costs (cost ratio), regulation and licensing shifts (barriers), and measured sector adoption (velocity) all re-enter at every index release. Each release is recomputed, versioned and kept queryable — scores are claims with a date on them, not permanent labels.